NCT04806919

Luteal Support in Artificial Vitrified/Warmed Cycles With Low Progesterone

Randomized Controlled Trial Comparing Micronized Progesterone (Amelgen ®) 400 mg BID Versus 400 mg TID for Luteal Support in Artificial Vitrified/Warmed Single Blastocyst Transfer Cycles With Low Progesterone on Day of Embryo Transfer

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 87 (actual)
• Sponsor: University Hospital, Ghent · Academic / Other
• Sex: Female
• Age: 18 Years – 43 Years
• Healthy volunteers: Not accepted

Summary

The study aims to evaluate the effect of an increased dose of vaginal progesterone supplementation on the incidence of ongoing pregnancy for patients with a suboptimal serum progesterone level (defined as \< 10 mcg/l) on the day of blastocyst transfer.

Conditions

• IVF
• Embryo Loss
• Luteal Phase Defect

Interventions

Type	Name	Description
DRUG	Progesteron TID	increasing the dose

Timeline

• Start date: 2021-04-02
• Primary completion: 2025-02-28
• Completion: 2025-03-31
• First posted: 2021-03-19
• Last updated: 2026-03-23

Locations

2 sites across 1 country: Belgium